Shanghai, China --- On April 29, 2020, MicroPort Scientific Corporation (hereinafter referred to as "Microport^®", stock code: 00853) announced today that it has reached an Agreement on Strategic Cooperation with Robocath Company (hereinafter referred to as "Robocath"). Robocath is located in France, and its business mainly includes R&D, production and sales of surgical robots for treating vascular diseases. As the leading investor, MicroPort^® has, in conjunction with Zhejiang Silk Road Fund, Luxembourg Investment Fund managed by Qidi Holdings, CS Group (Holding), Anaxago and the existing investors of Robocath, reached an agreement with Robocath to make a strategic investment of not more than 40 million Euros in total.

Meanwhile, Microport^® and Robocath have signed a Letter of Intent to jointly establish a joint venture in China, which will help Robcath's existing robot products to register for license from the NMPA, China, and conduct the commercial promotion. Factories built in China serve to produce and assemble robot systems and develop the next generation of robot systems and related AI technologies.

Dr. He Chao, General Manager of MicroPort^® MedBot, said: "We believe that the medical robot platform is bound to lead the emergence of the next generation of medical technology, such as telemedicine and AI, and ultimately promote the innovation and development of treatment methods. MicroPort^® and Robocath will make concerted efforts to push this revolutionary and innovative vascular interventional robot technology to the Chinese market."

Robocath was established in 2009, and its business mainly includes R&D, production and sales of surgical robots for treating vascular diseases. R-One™ is the first robot system developed by Robocath. It aims to assist cardiovascular interventional physicians in stent implantation (angioplasty) by providing sophisticated technology to assist the existing surgical operations. R-One™ has an open architecture and is compatible with the mainstream interventional instruments and catheter rooms on the market. In a prospective, randomized and controlled preclinical trial, the technical success rate of R-One™ reached 100% and no major cardiovascular adverse event (MACE) has occurred, which fully proves its safety and effectiveness. R-One™ was CE certified in February 2019, and it is the first robot system in Europe to obtain CE certification in interventional cardiology. At present, R-One™ has been promoted to markets in Europe and Africa.

Dr. Phillippe Bencteux, founder and chairman of Robocath, said: "This strategic investment is an important milestone for Robocath. It will enable us to obtain sufficient funds to start the further development of R-One and promote its commercialization. MicroPort^® is our best strategic partner in China, and I believe that the in-depth cooperation between the two parties will benefit the development of this product and technology in the Chinese market. We are looking forward to the early introduction of vascular interventional robot platform technology to the Chinese market."